ARS Pharmaceuticals, Inc. (SPRY) Shareholders’ equity 2021–2025
ARS Pharmaceuticals, Inc. (SPRY) shareholders’ equity at each fiscal year-end, per SEC filings.
$114.3MFY2025 · since FY2021: -$31.3M → $114.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $114.3M | -55.5% |
| FY2024 | $256.8M | +11.3% |
| FY2023 | $230.8M | -15.4% |
| FY2022 | $272.9M | +972.7% |
| FY2021 | -$31.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice